8-K: Candel Therapeutics Announces Positive Phase 3 Results and First Quarter 2025 Financials

Candel Therapeutics reports positive phase 3 clinical trial results for CAN-2409 in localized prostate cancer and provides a corporate update along with its first quarter 2025 financial results.

Summary

• Candel Therapeutics announced its financial results for the quarter ended March 31, 2025.
• The company highlighted positive phase 3 results for CAN-2409 in localized prostate cancer, which will be presented at the ASCO Annual Meeting.
• A BLA submission for CAN-2409 in prostate cancer is expected in Q4 2026.
• CAN-2409 also demonstrated prolonged median overall survival in NSCLC patients non-responsive to immune checkpoint inhibitors and notable improvement in mOS in pancreatic adenocarcinoma patients.
• Research and development expenses were $4.0 million for the first quarter of 2025, compared to $4.1 million for the first quarter of 2024.
• General and administrative expenses were $4.1 million for the first quarter of 2025, compared to $3.8 million for the first quarter of 2024.
• Net income for the first quarter of 2025 was $7.4 million, compared to a net loss of $8.2 million for the first quarter of 2024.
• Cash and cash equivalents were $92.2 million as of March 31, 2025, compared to $102.7 million as of December 31, 2024.
• The company expects its cash and cash equivalents to fund its operating plan into the first quarter of 2027.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical trial results, a strategic collaboration, and a sufficient cash runway. The company's progress towards BLA submission and potential commercialization of CAN-2409 contribute to the positive sentiment.

Positives

• Positive phase 3 clinical trial results for CAN-2409 in localized prostate cancer.
• CAN-2409 demonstrated meaningful overall survival benefits in patients with advanced NSCLC and borderline resectable PDAC.
• FDA Fast Track Designation for CAN-2409 in multiple indications validates its potential.
• Strategic commercial collaboration with IDEA Pharma to support CAN-2409 development and commercialization.
• Appointment of Elizabeth M. Jaffee, M.D., to the Research Advisory Board.
• Publication of encouraging clinical and immunological biomarker data in Neuro-Oncology.
• The company's cash position is expected to fund operations into the first quarter of 2027.
• Net income for the first quarter of 2025 was $7.4 million compared to a net loss of $8.2 million for the first quarter of 2024.

Negatives

• Research and development expenses decreased slightly from $4.1 million in Q1 2024 to $4.0 million in Q1 2025.
• Cash and cash equivalents decreased from $102.7 million as of December 31, 2024, to $92.2 million as of March 31, 2025.

Risks

• The timing and advancement of development programs are subject to risks and uncertainties.
• Final data from preclinical studies and clinical trials may differ materially from reported interim data.
• The company's ability to obtain and maintain regulatory approval of product candidates is not guaranteed.
• The company's ability to maintain its intellectual property is subject to risks.
• The implementation of the company's business model and strategic plans is subject to risks.

Future Outlook

The company expects its existing cash and cash equivalents to be sufficient to fund its current operating plan into the first quarter of 2027. The company anticipates reporting clinical and biomarker activity data from an ongoing phase 1b clinical trial evaluating repeat doses of CAN-3110 in patients with rHGG in Q4 2025 and expects to submit a BLA for CAN-2409 in prostate cancer in Q4 2026.

Management Comments

• During the quarter, we continued our strong momentum of compelling clinical evidence, reinforcing our promising pipeline of pan solid tumor immunotherapies, said Paul Peter Tak, MD PhD FMedSci, President and CEO of Candel.
• Our primary focus for 2025 remains on working toward CAN-2409s BLA submission for prostate cancer, which we believe represents a very significant unmet medical need and opportunity for value creation.
• CAN-2409, Candels most advanced multimodal biological immunotherapy candidate, continues to demonstrate meaningful overall survival benefits in patients with advanced NSCLC, non-responsive to immune checkpoint inhibitors, as well as in patients with borderline resectable PDAC.
• The totality of data showing notable extension of survival based on both phase 2a clinical trials in NSCLC and PDAC, respectively, suggests that CAN-2409 has the potential to represent a transformative treatment option for patients with difficult-to-treat solid tumors.

Industry Context

Candel's focus on multimodal biological immunotherapies aligns with the growing trend in oncology towards personalized and immune-based treatments. The positive results for CAN-2409 in multiple solid tumors position the company as a potential key player in the field.

Comparison to Industry Standards

• The median overall survival of 24.5 months observed in NSCLC patients inadequately responding to ICI treatment compares favorably to the 9.8-11.8 months reported in published literature for the same patient population receiving standard of care docetaxel chemotherapy.
• The mOS of 31.4 months in borderline resectable PDAC patients treated with CAN-2409 and chemoradiotherapy is a notable improvement compared to the 12.5 months observed in the control arm treated with chemoradiotherapy alone.
• Companies like BioNTech and Moderna have also been exploring mRNA-based cancer vaccines, while others like Amgen and Kite Pharma are focused on cell therapies. Candel's approach using viral vectors offers a different modality with its own set of advantages and challenges.

Stakeholder Impact

• Shareholders: Positive clinical trial results and financial performance may increase shareholder value.
• Patients: CAN-2409 has the potential to provide a new treatment option for patients with difficult-to-treat solid tumors.
• Employees: The company's progress may create new job opportunities and enhance employee morale.

Next Steps

• Present positive phase 3 results of CAN-2409 in prostate cancer at the 2025 ASCO Annual Meeting.
• Continue preparations for BLA submission for CAN-2409 in prostate cancer, expected in Q4 2026.
• Report biomarker and initial survival data from ongoing phase 1b clinical trial evaluating repeat doses of CAN-3110 in patients with rHGG, expected in Q4 2025.

Key Dates

Keywords

CAN-2409, Candel Therapeutics, Prostate Cancer, NSCLC, PDAC, Immunotherapy, Clinical Trial, BLA, Financial Results, ASCO